Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-005 in paroxysmal nocturnal hemoglobinuria
NCT07212426Phase 2Active, not recruiting
- Sponsor
- LongBio Pharma
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by LongBio Pharma. Started Nov 2024; status: active, not recruiting.
02
Drugs
LP-005
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07212426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07212426.